Religox is indicated for the management of adult patients with advanced prostate cancer.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Relugolix is a non-peptide, small-molecule GnRH receptor antagonist. It binds competitively to pituitary GnRH receptors, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in suppression of testosterone production, which is essential in controlling prostate cancer progression.
Common (≥10%):
Less common / Rare:
Loading Dose: 360 mg orally on Day 1.
Maintenance Dose: 120 mg once daily, taken at the same time each day (with or without food).
Missed Dose:
Pediatric use: Not established.
Geriatric use: No clinically significant difference observed compared to younger patients.
P-gp inhibitors: Avoid co-administration. If necessary, take Religox first, maintain a 6-hour gap, and monitor closely.
Strong CYP3A inducers (combined with P-gp): Avoid. If unavoidable, increase dose to 240 mg once daily.
Not indicated for use in women.
Safety and efficacy in pregnancy and lactation have not been established.
QT prolongation: Monitor in patients at risk or on QT-prolonging drugs.
Embryo-fetal toxicity: May cause fetal harm; advise contraception for men with female partners of reproductive potential.
Fertility: Relugolix may impair male fertility.
Store in a cool, dry place, protected from light and moisture.
Keep out of reach of children.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.